Science Corporation: Pioneering Organ Perfusion to Extend Human Organ Lifespan

Company Overview

Science Corporation, a brain-computer interface (BCI) startup founded in 2021 by former Neuralink President Max Hodak, has announced the launch of a new division focused on extending the lifespan of human organs—marking a strategic expansion beyond its initial focus on neural interfaces. Headquartered in Alameda, California, the company aims to revolutionize organ preservation and life support systems by developing a novel, portable, and cost-effective perfusion platform.

Founder and Organizational Background

Max Hodak, a key figure in neurotechnology, co-founded Neuralink with Elon Musk in 2016 before departing in 2021 to establish Science. Since its inception, Science has secured approximately $290 million in funding, as reported by venture capital database Pitchbook, reflecting investor confidence in its dual focus on neural interfaces and organ longevity technologies.

Previously, Science prioritized neural interfaces and vision restoration. The company is developing a "biohybrid" interface that uses living neurons (rather than wires) to connect with the brain, alongside commercializing a retinal implant acquired from French startup Pixium Vision in 2024. This implant, which restores vision in patients with advanced macular degeneration, has enabled users to read text, positioning Science ahead of competitors like Neuralink in vision restoration.

Strategic Pivot: From Neural Interfaces to Organ Perfusion

While organ perfusion was not initially Science’s core focus, Hodak’s motivation stemmed from a poignant case: a 17-year-old Boston boy with cystic fibrosis whose lungs failed. Treated with extracorporeal membrane oxygenation (ECMO)—a short-term life support measure—he was denied a transplant due to complications, leading to his death after ECMO equipment failure. This experience highlighted the limitations of current systems.

Hodak recognized ECMO’s flaws: it is resource-intensive, costly ($1000–$3000/day), bulky (requiring bedside carts and constant manual adjustments), and unavailable in many hospitals. Additionally, organ perfusion systems for transplants, such as TransMedics’ Organ Care System, cost $250,000 upfront plus $40,000–$80,000 per use, with organs often transported via private jets—a model that is financially and logistically prohibitive.

Innovation: Science’s Organ Perfusion System

Science’s proprietary system addresses these gaps through technological innovation:

• Current Capabilities: A small team has developed a modular, portable platform that sustained rabbit kidneys for 48 hours ex vivo, with plans to extend this to one month by spring 2025.

• Technical Features: Integrated real-time sensors monitor blood oxygenation, flow rate, pressure, and temperature. A closed-loop control system enables automated adjustments, eliminating the need for manual oversight required by current ECMO and TransMedics devices.

• Viability Targets: Human kidneys typically survive 24–36 hours ex vivo (on ice); Science’s system extends this to 4+ days, rivaling or exceeding existing perfusion technologies.

Competitive Landscape and Market Vision

Science will compete with established players in automated organ perfusion, including TransMedics and Getinge, but aims to reduce costs and increase portability. While existing systems require specialized training and high operational costs, Science’s design prioritizes affordability and user-friendliness, with modular components to support different organs (e.g., kidneys, lungs) and applications (transplant preservation, life support).

Hodak envisions a paradigm shift: "Closing the gap between technology potential and daily clinical use would transform conventional medicine into a system of swappable parts," enabling portable, low-cost organ support akin to "checking a kidney as luggage on a flight"—a stark contrast to today’s tethered, hospital-bound equipment.

Conclusion: With 170 employees and a focus on bridging technological capability and practical deployment, Science aims to redefine organ preservation, moving beyond the limitations of current systems to a future where organ viability and support become scalable, accessible, and transformative.